Article thumbnail

Selective adenosine A2A receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects

By Irene Paterniti, Alessia Melani, Sara Cipriani, Francesca Corti, Tommaso Mello, Emanuela Mazzon, Emanuela Esposito, Placido Bramanti, Salvatore Cuzzocrea and Felicita Pedata
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). A: Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway. Mol Med
  2. (2006). Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation.
  3. (2005). Adenosine in tissue protection and tissue re generation. Mol Pharmacol
  4. (2008). Adenosine modulates excitatory synaptic transmission and suppresses neuronal death induced by ischaemia in rat spinal motoneurones. Pflugers Arch
  5. (2004). Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiol Dis
  6. (1996). Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.
  7. (2002). Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.
  8. (2000). Borea PA: A(2A) adenosine receptors in human peripheral blood cells.
  9. (2005). Cominelli F: Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology
  10. (1999). CS: Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology.
  11. (2006). Cuzzocrea S: Modulation of nitric oxide homeostasis in a mouse model of spinal cord injury.
  12. (2010). Cuzzocrea S: Selective adenosine A(2a) receptor agonists reduce the apoptosis in an experimental model of spinal cord trauma. J Biol Regul Homeost Agents
  13. (2009). Cuzzocrea S: The selective adenosine A2A receptor agonist CGS 21680 reduces JNK MAPK activation in oligodendrocytes in injured spinal cord. Shock
  14. (2005). CY: JNK activation contributes to DP5 induction and apoptosis following traumatic spinal cord injury. Neurobiol Dis
  15. (2007). de Mendonça A: Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation. Prog Neurobiol
  16. (2006). Degenerative and spontaneous regenerative processes after spinal cord injury.
  17. (2005). EA: Characterization of a new rat model of experimental combined neurotrauma. Shock
  18. (1999). Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation.
  19. (2006). Fehlings MG: Pharmacological approaches to repair the injured spinal cord.
  20. (1998). Hasko G: Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists.
  21. (2000). HI: Developmental expression of OSP/claudin-11.
  22. (2006). HS: Neutralization of the chemokine CXCL10 reduces apoptosis and increases axon sprouting after spinal cord injury.
  23. (2000). Hughes MG: Adenosine release upon spinal cord injury. Brain Res
  24. (2002). JA: Adenosine A2A agonist reduces paralysis after spinal cord ischemia: correlation with A2A receptor expression on motor neurons. Ann Thorac Surg
  25. (2002). JA: Adenosine A2A analogue improves neurologic outcome after spinal cord trauma in the rabbit.
  26. (2004). JA: Adenosine A2A analogue reduces long-term neurologic injury after blunt spinal trauma.
  27. (2010). JF: Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury.
  28. (1994). Kouchoukos NT: Dextrorphan inhibits the release of excitatory amino acids during spinal cord ischemia. Ann Thorac Surg
  29. (1995). Kouchoukos NT: Profound systemic hypothermia inhibits the release of neurotransmitter amino acids in spinal cord ischemia. J Thorac Cardiovasc Surg
  30. (2004). Marcillo A: The pathology of human spinal cord injury: defining the problems.
  31. (2004). Molecular mechanisms of glutamatedependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci
  32. (2006). Mouse spinal cord compression injury is reduced by either activation of the adenosine A2A receptor on bone marrow-derived cells or deletion of the A2A receptor on non-bone marrow-derived cells. Neuroscience
  33. (1998). MP: Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med
  34. (2004). Nö renberg W, Illes P: Adenosine A2A receptor-induced inhibition of NMDA and GABAA receptor-mediated synaptic currents in a subpopulation of rat striatal neurons. Neuropharmacology
  35. (1994). Nomenclature and classification of purinoceptors. Pharmacol Rev
  36. (1997). Olsson Y: Effects of moderate hypothermia on extracellular lactic acid and amino acids after severe compression injury of rat spinal cord.
  37. (1998). Ongini E: Cardiovascular pharmacology of the A2A adenosine receptor antagonist, SCH 58261, in the rat. J Pharmacol Exp Ther
  38. (1993). Pathophysiology of spinal cord trauma. Ann Emerg Med
  39. (2006). PB: Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis.
  40. (2008). Pedata F: Modulation of ischemic brain injury and neuroinflammation by adenosine A2A receptors. Curr Pharm Des
  41. (2009). Pedata F: Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia. Brain
  42. (2000). Pedata F: Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. Neuroreport
  43. (1999). Pedata F: Striatal A2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats. Neuroreport
  44. (2006). Pedata F: The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Res
  45. (2003). Pedata F: The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res
  46. (2006). Perinatal white matter injury: the changing spectrum of pathology and emerging insights into pathogenetic mechanisms. Ment Retard Dev Disabil Res Rev
  47. (2003). Peroxynitrite generated in the rat spinal cord induces oxidation and nitration of proteins: reduction by Mn (III) tetrakis (4-benzoic acid) porphyrin.
  48. (2004). Petratos S: Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol Dis
  49. (2006). PG: Basso Mouse Scale for locomotion detects differences in recovery after Paterniti et al.
  50. (1991). Review of experimental spinal cord injury with emphasis on the local and systemic circulatory effects. Neurochirurgie
  51. (2007). Role of peroxynitrite in secondary oxidative damage after spinal cord injury.
  52. (1997). Sá nchez-Gó mez MV, Martí nez-Millá n L, Miledi R: Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc Natl Acad Sci USA
  53. (2002). Sá nchez-Gó mez MV: Excitotoxicity in glial cells.
  54. (2001). SCH 58261 (an adenosine A(2A) receptor antagonist) reduces, only at low doses, K (+)-evoked glutamate release in the striatum.
  55. (1999). Schwarzschild MA: A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice.
  56. (2004). Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat Med
  57. (2006). Selmaj K: TRAIL-induced death of human adult oligodendrocytes is mediated by JNK pathway. Glia
  58. (2004). Skaper SD: Excitatory amino acid induced oligodendrocyte cell death in vitro: receptor-dependent and -independent mechanisms.
  59. (2000). Szabo C: Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. Faseb J
  60. (1978). Tator CH: Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat. Surgical neurology
  61. (1995). The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res
  62. (2006). The quest to repair the damaged spinal cord. Recent Pat CNS Drug Discov
  63. (2009). Triggering neurotrophic factor actions through adenosine A2A receptor activation: implications for neuroprotection.
  64. (1998). TW: Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A2A receptor antagonist. Brain Res
  65. (1998). TW: Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists. Neuroscience
  66. (2003). Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol
  67. (2006). ZQ: Poly (ADP-ribose) glycohydrolase activity mediates post-traumatic inflammatory reaction after experimental spinal cord trauma. J Pharmacol Exp Ther